Jocelyne Flament

1.4k total citations
31 papers, 955 citations indexed

About

Jocelyne Flament is a scholar working on Hematology, Pathology and Forensic Medicine and Biochemistry. According to data from OpenAlex, Jocelyne Flament has authored 31 papers receiving a total of 955 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Hematology, 10 papers in Pathology and Forensic Medicine and 10 papers in Biochemistry. Recurrent topics in Jocelyne Flament's work include Blood transfusion and management (10 papers), Lymphoma Diagnosis and Treatment (10 papers) and Platelet Disorders and Treatments (7 papers). Jocelyne Flament is often cited by papers focused on Blood transfusion and management (10 papers), Lymphoma Diagnosis and Treatment (10 papers) and Platelet Disorders and Treatments (7 papers). Jocelyne Flament collaborates with scholars based in United States, France and Germany. Jocelyne Flament's co-authors include Hervé Ghesquières, Qian Shi, Corinne Haïoun, Hervé Tilly, David Cunningham, Marita Ziepert, Harald Klüter, Norbert Schmitz, Christopher R. Flowers and Karin Janetzko and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Diabetes.

In The Last Decade

Jocelyne Flament

31 papers receiving 917 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jocelyne Flament United States	17	327	269	228	211	157	31	955
Jonathan P. Kerr United Kingdom	8	133 0.4×	150 0.6×	205 0.9×	256 1.2×	49 0.3×	11	818
M. Wolf Australia	15	272 0.8×	238 0.9×	287 1.3×	725 3.4×	40 0.3×	32	1.3k
Peter A.W. te Boekhorst Netherlands	21	97 0.3×	208 0.8×	263 1.2×	582 2.8×	129 0.8×	50	1.1k
H. Braine United States	17	65 0.2×	292 1.1×	323 1.4×	707 3.4×	94 0.6×	25	1.1k
Renée M. Y. Barge Netherlands	23	88 0.3×	92 0.3×	343 1.5×	504 2.4×	56 0.4×	44	1.5k
N. Duédari France	18	96 0.3×	221 0.8×	48 0.2×	734 3.5×	70 0.4×	47	1.1k
Jeane P. Hester United States	19	96 0.3×	63 0.2×	282 1.2×	381 1.8×	44 0.3×	51	907
Seth A. Rudnick United States	15	56 0.2×	297 1.1×	302 1.3×	664 3.1×	57 0.4×	23	1.3k
Isaac Djerassi United States	22	70 0.2×	174 0.6×	470 2.1×	424 2.0×	52 0.3×	38	1.3k
Jennifer Herring United States	11	81 0.2×	68 0.3×	347 1.5×	153 0.7×	17 0.1×	21	788

Countries citing papers authored by Jocelyne Flament

Since Specialization

Citations

This map shows the geographic impact of Jocelyne Flament's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jocelyne Flament with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jocelyne Flament more than expected).

Fields of papers citing papers by Jocelyne Flament

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jocelyne Flament. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jocelyne Flament. The network helps show where Jocelyne Flament may publish in the future.

Co-authorship network of co-authors of Jocelyne Flament

This figure shows the co-authorship network connecting the top 25 collaborators of Jocelyne Flament. A scholar is included among the top collaborators of Jocelyne Flament based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jocelyne Flament. Jocelyne Flament is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ruppert, Amy S., Jesse G. Dixon, Gilles Salles, et al.. (2020). International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Blood. 135(23). 2041–2048. 199 indexed citations

Péron, Julien, Sandrine Marréaud, Tiana Raveloarivahy, et al.. (2019). A multinational, multi-tumour basket study in very rare cancer types: The European Organization for Research and Treatment of Cancer phase II 90101 ‘CREATE’ trial. European Journal of Cancer. 109. 192–195. 12 indexed citations

Pochet, Sylvie, et al.. (2018). A simple micro-batch ion-exchange resin extraction method coupled with reverse-phase HPLC (MBRE-HPLC) to quantify lactoferrin in raw and heat-treated bovine milk. Food Chemistry. 259. 36–45. 28 indexed citations

Shi, Qian, Norbert Schmitz, Fang‐Shu Ou, et al.. (2018). Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient–Level Analysis of Multiple Randomized Trials (SEAL). Journal of Clinical Oncology. 36(25). 2593–2602. 47 indexed citations

Maurer, Matthew J., Thomas M. Habermann, Qian Shi, et al.. (2018). Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials. Annals of Oncology. 29(8). 1822–1827. 47 indexed citations

Maurer, Matthew J., Thomas M. Habermann, Qian Shi, et al.. (2016). Utility of Progression-Free Survival at 24 Months (PFS24) to Predict Subsequent Outcome for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Enrolled on Randomized Clinical Trials: Findings from a Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 5853 Patients. Blood. 128(22). 3027–3027. 5 indexed citations

Nowakowski, Grzegorz S., Annalisa Chiappella, Thomas E. Witzig, et al.. (2016). ROBUST: Lenalidomide-R-Chop Versus Placebo-R-Chop in Previously Untreated Abc-Type Diffuse Large B-Cell Lymphoma. Future Oncology. 12(13). 1553–1563. 62 indexed citations

Nowakowski, Grzegorz S., Annalisa Chiappella, Thomas E. Witzig, et al.. (2016). Feasibility of real-time cell-of-origin subtype identification by gene expression profile in the phase 3 trial of lenalidomide plus R-CHOP vs placebo plus R-CHOP in patients with untreated ABC-type diffuse large B-cell lymphoma (ROBUST).. Journal of Clinical Oncology. 34(15_suppl). 7538–7538. 2 indexed citations

Bean, John P., et al.. (2010). The European Organisation for Research and Treatment of Cancer Imaging Programme. European Oncology & Haematology. 6(1). 92–92. 2 indexed citations

10.

Wallace, Mark S., et al.. (2009). The INFUSE-Morphine Study: Use of Recombinant Human Hyaluronidase (rHuPH20) to Enhance the Absorption of Subcutaneously Administered Morphine in Patients with Advanced Illness. Journal of Pain and Symptom Management. 38(5). 663–672. 30 indexed citations

11.

Hervig, Tor, José Luis Bueno, Emma Castro, et al.. (2008). A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment. Transfusion. 48(6). 1061–1071. 79 indexed citations

12.

Johansson, Pär I., Maureen G. Conlan, Michèle Jacquet, et al.. (2006). Transfusion of 7‐day‐old amotosalen photochemically treated buffy‐coat platelets to patients with thrombocytopenia: a pilot study. Transfusion. 46(3). 424–433. 32 indexed citations

13.

Janetzko, Karin, Jean‐Pierre Cazenave, Harald Klüter, et al.. (2005). Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set. Transfusion. 45(9). 1443–1452. 102 indexed citations

14.

Doyen, Chantal, et al.. (2005). Routine Use of Platelet Components Prepared with Photochemical Treatment (INTERCEPT Platelets™): Impact on Clinical Outcomes and Resources.. Blood. 106(11). 429–429. 8 indexed citations

15.

Gulliksson, H., Jean‐Pierre Cazenave, Derwood Pamphilon, et al.. (2004). Therapeutic efficacy of pooled buffy‐coat platelet components prepared and stored with a platelet additive solution. Transfusion Medicine. 14(4). 289–295. 18 indexed citations

16.

Janetzko, Karin, L. Lin, Hermann Eichler, et al.. (2004). Implementation of the INTERCEPT Blood System for Platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets. Vox Sanguinis. 86(4). 239–245. 51 indexed citations

17.

Gulliksson, H., et al.. (1997). A system for the supply of platelets suspended in a storage medium including buffy-coat-derived platelet concentrates in combination with “split” apheresis platelets. Transfusion Science. 18(1). 33–40. 12 indexed citations

18.

Müller‐Steinhardt, Michael, et al.. (1997). Impact of various red cell concentrate preparation methods on the efficiency of prestorage white cell filtration and on red cells during storage for 42 days. Transfusion. 37(11-12). 1137–1142. 24 indexed citations

19.

Moore, Glenn A., et al.. (1997). Prestorage Leukocyte Reduction with In‐Line Filtration of Whole Blood: Evaluation of Red Cells and Plasma Storage. Vox Sanguinis. 73(1). 28–35. 33 indexed citations

20.

Carlier, Yves, et al.. (1992). Chagas' Disease: Decreased Resistance to Trypanosoma Cruzi Acquired Infection in Offspring of Infected Mice. American Journal of Tropical Medicine and Hygiene. 46(2). 116–122. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact